stem cell mobilization


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

stem cell mobilization

The stimulation of bone marrow (with intensive cancer chemotherapies or blood-forming growth factors) to release stem cells into the peripheral blood. The cells that appear in the blood can be harvested for use in autologous bone marrow transplantation. Mobilized cells (identified by the cell surface marker CD34) are returned to the patient after chemotherapy or radiation therapy so that the treated patient can ultimately resume making healthy blood cells on his own.
See also: mobilization
Mentioned in ?
References in periodicals archive ?
Jessica has experienced numerous benefits as a result of the stem cell mobilization protocol.
A pioneering treatment for scleroderma ... an incurable disease
These proposals supersede several existing patents on stem cell mobilization.
Stem cell support: the nutraceutical induction of adult stem cell recruitment (IASCR)
This study involving human stem cell mobilization was triggered by a few cases of empirical evidence that consumption of an extract from AFA, enriched for the LSL, resulted in an unexpected extent of recovery after traumatic injuries to the central nervous system.
Mobilization of human CD[34 sup.+] CD[133 sup.+] and CD[34 sup.+] CD[133.sup.-] stem cells in vivo by consumption of an extract from Aphanizomenon flosaquae--related to modulation of CXCR4 expression by an L-selection ligand?
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma.
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
23, 2014 -- BioLineRx (BLRX) has received notice from the FDA confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for acute
Orphan Drug Designation for novel stem cell mobilization treatment
Standard of care for patients with refractory or relapsing disease after initial therapy consists of a salvage therapy comprising a conventional chemotherapy regimen usually followed by stem cell mobilization and subsequent high-dose chemotherapy along with autologous stem cell transplantation.
4SC's Resminostat receives FDA Orphan Drug Status for Hodgkin's Lymphoma
The CXCR4/SDF-1 axis has been shown to play a role in stem cell mobilization, vasculogenesis, tumor growth and metastasis.
NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer[R] NOX-A12
The first approved and marketed drug is plerixafor (AMD3100), a small molecule inhibitor of the CXCR-4/SDF-1 axis, used for stem cell mobilization.
Research and Markets: A Comprehensive Competitor Analysis on CXCR and CXCL Agonists and Antagonists
Frank Morich, Chief Executive Officer of NOXXON, commented: "Based on exceptionally positive pre-clinical data, we strongly believe that, NOX-A12 has the potential to become an improved alternative for hematopoietic stem cell mobilization.
NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer[R] NOX-A12
The presentation titled, "Chemokine regulation of hematopoietic stem cell mobilization and angiogenesis" will be delivered on Friday, October 23, 2009 on behalf of OncoCyte Corporation and BioTime Asia.
Chief Medical Officer of BioTime's Subsidiary OncoCyte Corporation to Deliver Keynote Address at Fifth Chinese Congress on Stem Cell Therapy in Beijing, P.R. China
In the CXCR4 project, the in vivo results achieved with Ascent's novel lipopeptide Pepducins were at least as efficacious as those seen with Mozobil[R], a small molecule drug marketed by Genzyme which was recently approved for stem cell mobilization prior to bone marrow transplantation.
Ascent Therapeutics Achieves Preclinical in vivo Proof-of-Principle with Novel Pepducin[TM] GPCR Modulator Platform and Strengthens Senior Management Team
Biothera is currently conducting a Phase I/II clinical trial for stem cell mobilization and has several Phase II cancer trials planned for 2007.
Robert Brown Joins Biothera as Senior Vice President, Corporate Development

Medical browser ?
Full browser ?